Form 4: BioCardia CEO Peter Altman Reports Stock Transactions

BioCardia, Inc. reports on Form 4 detailing stock transactions by President and CEO Peter Altman, including withholding of shares for tax obligations and stock option grants.

Summary

• This filing is a Form 4, reporting changes in beneficial ownership of securities for Peter Altman, President and CEO of BioCardia, Inc.
• On July 2, 2026, 54,606 shares of common stock were withheld by the Issuer to satisfy tax obligations related to the net settlement of RSUs that vested on June 29, 2026. This is not a sale by the reporting person.
• An additional stock option grant was made, giving the right to buy 57,688 shares of common stock at an exercise price of $1.20 per share.
• This stock option vests and becomes exercisable in monthly installments starting August 6, 2026, with full vesting occurring over 48 months, contingent on continued service.
• Following these transactions, Peter Altman beneficially owns 356,585 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine executive compensation adjustments and tax settlements rather than significant strategic or financial performance indicators.

Positives

• The company is managing its tax obligations efficiently through share withholding, avoiding direct cash outflow from the executive.
• The issuance of stock options indicates a commitment to incentivizing executive performance and aligning interests with shareholders.
• Peter Altman continues to hold a significant direct beneficial ownership of 356,585 shares, demonstrating continued investment in the company.

Negatives

• A portion of vested RSUs were withheld for tax purposes, reducing the immediate net shares received by the executive.
• The stock option grant is subject to vesting over a 48-month period, meaning the full benefit is not immediately realized.

Risks

• The stock option grant's vesting is contingent on continued service, implying a risk of forfeiture if the reporting person departs.
• The withholding of shares for tax obligations, while standard, represents a reduction in the executive's immediate take-home equity.

Future Outlook

The stock option grant vests over 48 months, with the first tranche becoming exercisable on August 6, 2026, indicating a long-term incentive structure for the CEO.

Management Comments

• The reported securities represent shares withheld by the Issuer to satisfy income tax, withholding, and remittance obligations in connection with the net settlement of RSUs.
• This withholding does not represent a sale by the Reporting Person.
• The option vests and becomes exercisable as to 1/48th of the shares on August 6, 2026, and each month thereafter, subject to the Reporting Person continuing as a service provider.

Industry Context

StockSavvy.ai notes that executive stock option grants and RSU settlements are standard practices in the biotechnology sector to attract and retain key talent, aligning executive interests with long-term company performance.

Stakeholder Impact

• Shareholders: The transactions reflect standard executive compensation practices and do not immediately indicate a change in the company's strategic direction or financial health.
• Employees: The RSU settlement and option grant are part of the executive compensation structure, indirectly reflecting the company's ability to reward its leadership.
• Management: Peter Altman's continued direct ownership and receipt of stock options reinforce his commitment and alignment with the company's long-term success.

Next Steps

• Monthly vesting of stock options will continue from August 6, 2026, through July 2030, provided the reporting person remains a service provider.
• The reporting person will continue to beneficially own 356,585 shares of common stock directly.

Key Dates

Keywords

Form 4, SEC Filing, BioCardia, BCDA, Peter Altman, Stock Options, RSUs, Beneficial Ownership, Insider Trading, Executive Compensation